1. Home
  2. MGNX vs IH Comparison

MGNX vs IH Comparison

Compare MGNX & IH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

HOLD

Current Price

$1.88

Market Cap

115.8M

Sector

Health Care

ML Signal

HOLD

Logo iHuman Inc.

IH

iHuman Inc.

N/A

Current Price

$1.75

Market Cap

116.0M

Sector

Real Estate

ML Signal

N/A

Company Overview

Basic Information
Metric
MGNX
IH
Founded
2000
1996
Country
United States
China
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Other Consumer Services
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
115.8M
116.0M
IPO Year
2013
2020

Fundamental Metrics

Financial Performance
Metric
MGNX
IH
Price
$1.88
$1.75
Analyst Decision
Hold
Analyst Count
5
0
Target Price
$3.20
N/A
AVG Volume (30 Days)
533.9K
10.7K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
4.88%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$149,962,000.00
N/A
Revenue This Year
N/A
$39.02
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$7.30
Revenue Growth
155.26
N/A
52 Week Low
$0.99
$1.67
52 Week High
$2.49
$3.60

Technical Indicators

Market Signals
Indicator
MGNX
IH
Relative Strength Index (RSI) 57.06 39.51
Support Level $1.62 $1.75
Resistance Level $1.97 $2.29
Average True Range (ATR) 0.09 0.10
MACD 0.02 -0.01
Stochastic Oscillator 67.47 14.02

Price Performance

Historical Comparison
MGNX
IH

About MGNX MacroGenics Inc.

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

About IH iHuman Inc.

iHuman Inc is a Chinese company that uses artificial intelligence to create technology-driven puzzle products for children, making parenting easier and children happier. The company offers a range of intellectual development products that are designed to make the child-rearing experience more manageable for parents while turning intellectual development into a fun journey for children. Its revenue is generated from subscription fees paid by users for premium content on their self-directed and interactive online applications, as well as offline products and other sources.

Share on Social Networks: